Flanvotumab is used for its potent anti-tumor activity by targeting tyrosinase-related protein 1 (TYRP1), which is specifically expressed on melanocytes and melanoma cells, and functions through natural killer cell-mediated, antibody-dependent cellular cytotoxicity (ADCC); it exhibits favorable tolerability.